Awaiting development: Guidance and quality standards

Showing 91 to 100 of 285

Guidance and quality standards awaiting development
Title	Type
Enfortumab vedotin with pembrolizumab for neoadjuvant and adjuvant treatment of cisplatin-eligible muscle-invasive bladder cancer [ID6301]	Technology appraisal guidance
Ensitrelvir for treating COVID 19 [ID6231]	Technology appraisal guidance
Epcoritamab for treating relapsed or refractory diffuse large B-cell lymphoma after first-line systemic treatment ID 6463	Technology appraisal guidance
Eplontersen for treating transthyretin-related amyloidosis cardiomyopathy TSID 12015	Technology appraisal guidance
Estetrol for treating vasomotor symptoms associated with the menopause in people aged 40 to 65 ID4037	Technology appraisal guidance
Etrolizumab for treating moderately to severely active ulcerative colitis [ID3827]	Technology appraisal guidance
Favezelimab–pembrolizumab for previously treated PD-L1-positive metastatic colorectal cancer [ID6278]	Technology appraisal guidance
Favezelimab–pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma after anti-PD-L1 treatment [ID6393]	Technology appraisal guidance
Finerenone for treating heart failure with preserved or mildly reduced ejection fraction TS ID 12051	Technology appraisal guidance
Fostemsavir for treating adults with multidrug resistant HIV-1 for whom it is not possible to construct a suppressive anti-viral regimen [ID2726]	Technology appraisal guidance